Business Context and Reporting Period
This Form 6-K, filed on March 24, 2021, by Cellect Biotechnology, Ltd. (to be renamed Quoin Pharmaceuticals, Ltd.), reports the execution of material definitive agreements. The filing details a strategic merger with Quoin Pharmaceuticals, Inc., a private specialty pharmaceutical company focused on rare and orphan skin diseases. The transaction is designed to transform Cellect into a new entity focused on Quoin's pipeline, including treatments for Netherton Syndrome and Epidermolysis Bullosa.
Key Financial Metrics and Transaction Structure
The filing outlines a complex capital structure involving equity, debt, and asset divestiture rather than standard operating financial metrics.
- Equity Investment: A $25.25 million commitment from Altium Capital, consisting of $12 million in new funds and the conversion of $5 million in Bridge Notes.
- Bridge Financing: Up to $5,000,000 in aggregate principal amount of secured notes (Bridge Notes) to be issued in three tranches totaling $3,750,000 in purchase price.
- Asset Sale: Sale of Cellect Biotherapeutics, Ltd. (wholly-owned subsidiary) to EnCellX Inc. for royalty, milestone, and license fee payments.
- Ownership Structure: Post-closing, Quoin shareholders will own approximately 75% of the combined company, while pre-closing Cellect shareholders will retain approximately 25%, subject to dilution from the Altium Investment.
Material Changes Versus Prior Period
The filing represents a fundamental change in the company's business strategy and corporate identity rather than a period-over-period financial comparison.
- Corporate Identity: The company will change its name to "Quoin Pharmaceuticals, Ltd." and its Nasdaq trading symbol to "QNRX."
- Asset Portfolio: The company will divest its existing intellectual property and subsidiary (Cellect Biotherapeutics) to EnCellX, shifting its focus entirely to Quoin's rare disease pipeline.
- Capitalization: Significant dilution is expected for existing shareholders due to the issuance of shares to Quoin shareholders and the Altium Investment.
Guidance, Risks, and Contingencies
The transaction is contingent upon several conditions, including shareholder approval, effectiveness of a Form F-4 registration statement, and Nasdaq listing approval.
- Contingent Value Rights (CVRs): Pre-merger Cellect shareholders will receive CVRs entitling them to a pro-rata share of the net proceeds from the sale of Cellect Biotherapeutics to EnCellX.
- EnCellX Funding Condition: If EnCellX fails to raise at least $3,000,000 within 12 months of the share transfer closing to continue development, they must sell the subsidiary or its assets, with net proceeds payable to the CVR holders.
- Warrant Mechanics: The financing includes Series A, B, and C warrants with reset mechanics and escrow provisions for additional shares if the share price falls below 85% of specific averages.
- Risk Factors: The filing notes that the transaction is subject to customary closing conditions and that the representations in the agreements are for the benefit of the parties and may not reflect current facts.
Investor Verification Checklist
- Verify the final exchange ratio and the exact percentage of ownership for pre-closing Cellect shareholders post-dilution.
- Confirm the status of the Form F-4 registration statement and Nasdaq listing approval.
- Review the specific terms of the CVR Agreement regarding the calculation of net proceeds from the EnCellX transaction.
- Assess the terms of the Bridge Notes, including the security lien on Quoin's assets and the warrant exercise price of $48.51.
- Monitor the timeline for the three tranches of the Bridge Loan closing (March 25, April 23, and May 24, 2021).